The estimated Net Worth of Andrew H Galligan is at least $4.47 Million dollars as of 28 February 2020. Mr Galligan owns over 8,000 units of Nevro Corp stock worth over $289,618 and over the last 10 years he sold NVRO stock worth over $3,404,050. In addition, he makes $776,951 as Exec. Officer at Nevro Corp.
Mr has made over 27 trades of the Nevro Corp stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 8,000 units of NVRO stock worth $28,800 on 28 February 2020.
The largest trade he's ever made was exercising 134,100 units of Nevro Corp stock on 8 July 2019 worth over $120,690. On average, Mr trades about 9,533 units every 34 days since 2014. As of 28 February 2020 he still owns at least 61,490 units of Nevro Corp stock.
You can see the complete history of Mr Galligan stock trades at the bottom of the page.
Andrew H. Galligan is the Exec. Officer at Nevro Corp.
As the Exec. Officer of Nevro Corp, the total compensation of Mr Galligan at Nevro Corp is $776,951. There are 7 executives at Nevro Corp getting paid more, with D.Keith Grossman having the highest compensation of $13,877,700.
Mr Galligan is 65, he's been the Exec. Officer of Nevro Corp since . There are 2 older and 22 younger executives at Nevro Corp. The oldest executive at Nevro Corp is Frank Fischer, 78, who is the Independent Director.
Andrew's mailing address filed with the SEC is C/O OOMA, INC., 525 ALMANOR AVE., SUITE 200, SUNNYVALE, CA, 94085.
Over the last 10 years, insiders at Nevro Corp have traded over $298,472,982 worth of Nevro Corp stock and bought 312,708 units worth $8,709,518 . The most active insiders traders include Ali Behbahani, Holdings A/S Novo, and & Johnson Johnson & Johnson.... On average, Nevro Corp executives and independent directors trade stock every 18 days with the average trade being worth of $161,002. The most recent stock trade was executed by Shawn Mc Cormick on 7 June 2023, trading 7,500 units of NVRO stock currently worth $171,600.
headquartered in redwood city, california, nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. nevro has developed and commercialized the senza spinal cord stimulation (scs) system, an evidence-based neuromodulation platform for the treatment of chronic pain. the senza system is the only scs system that delivers nevro's proprietary hf10 therapy. the nevro® senza® scs system received ce mark in 2010, tga approval in 2011, fda approval in 2015, and is commercially available in europe, australia, and the united states.
Nevro Corp executives and other stock owners filed with the SEC include: